- Previous Close
0.3950 - Open
0.3950 - Bid 0.3550 x --
- Ask 0.3950 x --
- Day's Range
0.3700 - 0.4000 - 52 Week Range
0.1400 - 0.4800 - Volume
87,862 - Avg. Volume
153,950 - Market Cap (intraday)
47.545M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.
www.cleodx.comRecent News: COV.AX
View More
Performance Overview: COV.AX
Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COV.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COV.AX
View MoreValuation Measures
Market Cap
47.55M
Enterprise Value
48.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.55%
Return on Equity (ttm)
-88.99%
Revenue (ttm)
210.81k
Net Income Avi to Common (ttm)
-3.76M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
9.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-395.07k
Company Insights: COV.AX
COV.AX does not have Company Insights